AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Soda pdf professional 20133/14/2023 Among a propensity-matched sample, immunotherapy was associated with superior 3-year survival (52% vs 44% P < .001). Immunotherapy after chemotherapy and radiation was associated with reduced mortality (hazard ratio, 0.74 95% CI, 0.67-0.82 P < .001). Results A total of 23 811 patients with clinical stage III NSCLC with median (IQR) age 66 (59-72) years met inclusion criteria (10 454 women 564 Asian, 2930 Black, 20 077 White patients), including 209 (16.1%) patients with multiple comorbidities and 1297 (5.4%) immunotherapy recipients. Main Outcomes and Measures Mortality hazard in a multivariable Cox proportional hazards model and survival among a propensity-matched sample treated with chemotherapy and radiation, with and without immunotherapy. Objective To determine the outcomes of immunotherapy use in unresectable stage III NSCLC in the general US population.ĭesign, Setting, and Participants This cohort study analyzed the National Cancer Database for patients diagnosed with clinical stage III NSCLC between 20 with follow-up through the end of 2018 who were treated with chemotherapy and radiation. However, in the US, patients with NSCLC commonly differ from clinical trial populations in terms of age, health, access to care, and treatment course, which may all factor into the efficacy of immunotherapy. Importance The 2017 international PACIFIC trial established a role for immunotherapy after chemoradiation for unresectable stage III non–small cell lung cancer (NSCLC). Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine.Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography.Previously Reported Hazard Ratios for Overall Survival Comparing Durvalumab Plus Chemoradiation to Chemoradiation AloneĮTable 9. P Values Before and After Benjamini-Hochberg Multiple Testing Adjustment Cox Proportional Hazards Model of Patients Who Received Chemotherapy and Radiation With Immunotherapy for Stage III NSCLC With Time to Immunotherapy Within the PACIFIC Trial Limits and Outside the PACIFIC Trial Limits as a Covariate.ĮTable 8. Cox Proportional Hazards Model of Patients Who Received Chemotherapy and Radiation With Immunotherapy vs Patients Who Received Chemotherapy and Radiation Only for Stage III NSCLC With Time Between Radiation Completion and Starting Immunotherapy as a CovariateĮTable 7. ![]() Cox Proportional Hazards Model of Patients Who Received Chemotherapy and Radiation With Immunotherapy for Stage III NSCLC With Radiation Dose as a CovariateĮTable 6. Cox Proportional Hazards Model of Patients Who Received Chemotherapy and Radiation With Immunotherapy vs Patients Who Received Chemotherapy and Radiation Only for Stage III NSCLC With Radiation Doses as CovariatesĮTable 5. Cox Proportional Hazards Model of Stage III NSCLC Patients Who Received Chemotherapy and Radiation With Immunotherapy vs Chemotherapy and Radiation OnlyĮTable 4. Unmatched Kaplan-Meier Curve with Survival of Stage III NSCLC Patients Who Received Chemotherapy and Radiation Only Compared to Patients Who Received Chemotherapy and Radiation Followed by ImmunotherapyĮTable 3. ![]() Propensity-Matched Baseline Characteristics and Standardized Mean Differences of Patients Receiving Chemotherapy and Radiation Followed By Immunotherapy vs Chemotherapy and Radiation OnlyĮFigure.
0 Comments
Read More
Leave a Reply. |